How Novavax Is Keeping Up With the Big Players in the Coronavirus Vaccine Race
The coronavirus vaccine race is largely dominated by large drugmakers. AstraZeneca and Pfizer are evaluating COVID-19 vaccine candidates in late-stage testing. Johnson & Johnson plans to start its late-stage clinical study this month. Moderna is smaller than these big pharma companies, although it's not exactly tiny.
Then there's Novavax (NASDAQ: NVAX). The biotech's market cap of $6 billion is minuscule compared to the coronavirus vaccine leaders. But Novavax isn't too far behind the pack: It expects to begin a phase 3 trial of COVID-19 vaccine candidate NVX‑CoV2373 in the U.K. in September, with a U.S. late-stage study kicking off next month.
The reality is that Novavax is keeping up pretty well with the big players in the coronavirus vaccine race. Here's how.
Source Fool.com